Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 Market Cap is ₹875.6 Mil as of Aug. 20, 2026. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Invicta Diagnostic ranks worse than 83.8% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Invicta Diagnostic's share price for the quarter that ended in Mar. 2026 was ₹63. Invicta Diagnostic's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 12.6 Mil. Therefore, Invicta Diagnostic's market cap for the quarter that ended in Mar. 2026 was ₹792.0 Mil.
Invicta Diagnostic's quarterly market cap
stayed the same
from Mar. 2025 (₹0.0 Mil) to Sep. 2025 (₹0.0 Mil) but then
increased
from Sep. 2025 (₹0.0 Mil) to Mar. 2026 (₹792.0 Mil).
Invicta Diagnostic's annual market cap
stayed the same
from Mar. 2024 (₹0.0 Mil) to Mar. 2025 (₹0.0 Mil) but then
increased
from Mar. 2025 (₹0.0 Mil) to Mar. 2026 (₹792.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Invicta Diagnostic's Enterprise Value for Today is ₹690.2 Mil.
Invicta Diagnostic (NSE:INVICTA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Invicta Diagnostic Market Cap Related Terms
Invicta Diagnostic Market Cap Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic Market Cap Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
Market Cap
0.00
0.00
792.04
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
Market Cap
0.00
0.00
0.00
792.04
NSE:INVICTA vs TMO, DHR, IDXX: Market Cap Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's Market Cap distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Invicta Diagnostic's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic (NSE:INVICTA) has a Market Cap of ₹875.6 Mil as of Aug. 20, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Invicta Diagnostic and its competitors. According to the industry distribution chart, Invicta Diagnostic ranks #181 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 83.8%.
Is Invicta Diagnostic's Market Cap too high?
Invicta Diagnostic's current Market Cap is ₹875.6 Mil. Based on the distribution chart, Invicta Diagnostic ranks #181 out of 216 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #181 out of 216 companies for Market Cap. This places Invicta Diagnostic in the lower half of its industry. The industry median Market Cap is 63.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 63.43, based on 216 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Invicta Diagnostic and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 63.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invicta Diagnostic's current Market Cap is ₹875.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current Market Cap of ₹875.6 Mil. The current Market Cap is ₹875.6 Mil. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current Market Cap is ₹875.6 Mil as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
